Notably, PIK3CA expression did not correlate with clinical outcomes in this study (102) (102).In contrast, a phase Ib clinical trial (NCT02282371) evaluating alpelisib (BYL719), an oral class I α-specific PI3K inhibitor, in combination with cetuximab and IMRT, reported promising outcomes in patients with locally advanced HNSCC, particularly among those harboring PIK3CA mutations (73). The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.